Last reviewed · How we verify
VAX102
At a glance
| Generic name | VAX102 |
|---|---|
| Also known as | Universal influenza vaccine, STF2.4xM2e |
| Sponsor | VaxInnate Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults (PHASE1)
- Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults (PHASE1)
- Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults (PHASE1)
- Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAX102 CI brief — competitive landscape report
- VAX102 updates RSS · CI watch RSS
- VaxInnate Corporation portfolio CI